[go: up one dir, main page]

MX2017005530A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2017005530A
MX2017005530A MX2017005530A MX2017005530A MX2017005530A MX 2017005530 A MX2017005530 A MX 2017005530A MX 2017005530 A MX2017005530 A MX 2017005530A MX 2017005530 A MX2017005530 A MX 2017005530A MX 2017005530 A MX2017005530 A MX 2017005530A
Authority
MX
Mexico
Prior art keywords
combination
rgd
gly
asp
moiety
Prior art date
Application number
MX2017005530A
Other languages
English (en)
Inventor
Bernard March John
Mclntosh CLARK Ewan
Original Assignee
Big Dna Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1419311.4A external-priority patent/GB201419311D0/en
Priority claimed from GB201500681A external-priority patent/GB201500681D0/en
Priority claimed from GBGB1506673.1A external-priority patent/GB201506673D0/en
Application filed by Big Dna Ltd filed Critical Big Dna Ltd
Publication of MX2017005530A publication Critical patent/MX2017005530A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una combinación que comprende un inhibidor de proteasoma y un péptido cíclico que comprende un radical Arg-Gly-Asp (RGD) expuesto; en particular, la presente invención se refiere a una combinación que comprende un inhibidor de proteasoma seleccionado del grupo que consiste en: un boronato, una epoxicetona, un aldehído peptídico y un inhibidor de la proteasa ß-lactona; y un péptido cíclico que comprende un radical Arg-Gly-Asp (RGD) expuesto; más particularmente, la presente invención se refiere a una combinación que comprende un inhibidor de proteasoma seleccionado del grupo que consiste en: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 y marizomib; y un péptido cíclico que comprende un radical Arg-Gly-Asp (RGD) expuesto.
MX2017005530A 2014-10-30 2015-10-27 Terapia de combinacion. MX2017005530A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1419311.4A GB201419311D0 (en) 2014-10-30 2014-10-30 Combination therapy
GB201500681A GB201500681D0 (en) 2015-01-15 2015-01-15 Combination therapy
GBGB1506673.1A GB201506673D0 (en) 2015-04-20 2015-04-20 Combination therapy
PCT/GB2015/053215 WO2016067010A1 (en) 2014-10-30 2015-10-27 Combination therapy

Publications (1)

Publication Number Publication Date
MX2017005530A true MX2017005530A (es) 2017-12-20

Family

ID=54478173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005530A MX2017005530A (es) 2014-10-30 2015-10-27 Terapia de combinacion.

Country Status (11)

Country Link
US (2) US10328116B2 (es)
EP (1) EP3212210B1 (es)
JP (1) JP6592097B2 (es)
KR (1) KR20170082523A (es)
CN (1) CN106999540B (es)
AU (1) AU2015340359B2 (es)
BR (1) BR112017008290A2 (es)
CA (1) CA2966288A1 (es)
MX (1) MX2017005530A (es)
WO (1) WO2016067010A1 (es)
ZA (1) ZA201702522B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2554333A (en) * 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US20180078532A1 (en) * 2016-09-21 2018-03-22 Amgen Inc. Immediate release formulations for oprozomib
WO2018167295A1 (en) * 2017-03-17 2018-09-20 Technische Universität München LIGANDS FOR INTEGRIN αvβ8, SYNTHESIS AND USES THEREOF
JP2021504475A (ja) * 2017-11-22 2021-02-15 ヒルストリーム・バイオファーマ・インコーポレイテッド ボルテゾミブを含むポリマーナノ粒子
CN115279339A (zh) * 2020-01-10 2022-11-01 美国安进公司 稳定的无环糊精的卡非佐米配制品
MX2022010327A (es) * 2020-03-03 2022-11-09 Active Biotech Ab Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada.
CN113209303B (zh) * 2021-05-18 2023-03-17 上海交通大学医学院 Wwp1通过溶酶体途径降解癌蛋白muc1抑制肿瘤及其应用
CN113413460A (zh) * 2021-08-10 2021-09-21 中山大学·深圳 Traf6抑制剂在制备黑色素瘤药物中的应用
CN116763743A (zh) * 2023-06-30 2023-09-19 西北工业大学 一种自组装硼替佐米纳米药物的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
WO2010096627A1 (en) * 2009-02-20 2010-08-26 Lisanti Michael P Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
DK2519231T3 (en) * 2009-10-01 2017-06-26 Janssen Pharmaceutica Nv Proteasome inhibitors for the treatment of cancer
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
CN103153328A (zh) * 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
RU2013154355A (ru) * 2011-06-03 2015-07-20 Ф. Хоффманн-Ля Рош Аг Способ лечения мезотелиомы ингибитором рi3к
AU2012266803B2 (en) 2011-06-09 2017-02-02 Merck Patent Gmbh Treatment of cancers and metastases with suspensions of cilengitide in carrier
US20150071918A1 (en) * 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
WO2014084378A1 (ja) 2012-11-29 2014-06-05 国立大学法人 東京大学 環状ｒｇｄ配列含有ペプチドを含む抗癌剤

Also Published As

Publication number Publication date
JP2017537974A (ja) 2017-12-21
US20190175687A1 (en) 2019-06-13
EP3212210B1 (en) 2019-12-11
AU2015340359B2 (en) 2019-11-21
EP3212210A1 (en) 2017-09-06
KR20170082523A (ko) 2017-07-14
JP6592097B2 (ja) 2019-10-16
CN106999540A (zh) 2017-08-01
AU2015340359A1 (en) 2017-04-27
US20180021403A1 (en) 2018-01-25
ZA201702522B (en) 2019-10-30
US10328116B2 (en) 2019-06-25
WO2016067010A1 (en) 2016-05-06
BR112017008290A2 (pt) 2017-12-19
CA2966288A1 (en) 2016-05-06
CN106999540B (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
MX2017005530A (es) Terapia de combinacion.
AU2015208932A8 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
PH12012502259A1 (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
MX394503B (es) Composicion envasada.
EA201790747A1 (ru) Устройство для генерации аэрозоля
MX2016011556A (es) Composiciones que comprenden un agente amargante.
ZA201506572B (en) Tripeptide epoxy ketone protease inhibitors
TWD168095S (zh) 瓶子
IL258297B (en) Epoxy ketone dipeptide and tripeptide as protease inhibitors
SG10201900574SA (en) Virtual currency conversion device, method and computer program
TWD168096S (zh) 瓶子
TWD168213S (zh) 香水瓶
MX2016011558A (es) Composiciones que comprenden un agente amargante.
TW201614613A (en) Display device
EP4410374A3 (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
MX365086B (es) Aparato y metodo para generar una senal mejorada usando relleno de ruido independiente.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
SE542188C2 (en) Supports for membrane enhanced peptide synthesis
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
PH12020550538A1 (en) Method for the synthesis of cyclic depsipeptides
MX2014012056A (es) Metodo y dispositivo para incitar al usuario.
GB2515959A (en) Techniques for creasing a cover of a case